Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 14 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 11458107

    Abiotic anti-VEGF nanoparticle

    The Regents of the University of California · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

  2. US 11459374

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

  3. US 11459385

    Anti-IL-2 antibodies and compositions and uses thereof

    The Regents of the University of California · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

  4. US 11453719

    Compositions and methods for treating cancer with anti-ROR1 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted

  5. US 11453721

    Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted

  6. US 11446302

    Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations

    The Board of Regents of the University of Texas System · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted

  7. US 11447541

    Anti-coronavirus antibodies and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Svcs. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted

  8. US 11439683

    Anti-angiogenic therapy of metastatic colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted

  9. US 11440956

    Anti-thyroglobulin T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted

  10. US 11440950

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted

  11. US 11433013

    Peptide for preventing skin damage caused by air pollutants and for anti-aging, and use thereof

    CAREGEN CO., LTD. · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  12. US 11434301

    Anti-CD46 antibodies and methods of use

    The Regents of the University of California · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  13. US 11434304

    Anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  14. US 11434272

    Anti-human papillomavirus 16 E7 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  15. US 11427634

    Human anti-semaphorin 4D antibody

    VACCINEX, INC. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  16. US 11426467

    Dosage regimes for the administration of an anti-CD25 ADC

    ADC THERAPEUTICS SA · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  17. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted

  18. US 11420976

    Heterocyclic compounds as anti-viral agents

    Enanta Pharmaceuticals, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted

  19. US 11414496

    Anti-CD38 binding domains

    Takeda Pharmaceutical Company Limited · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  20. US 11414494

    Anti-GITR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  21. US 11406724

    Stabilized radiolabeled anti-CD45 immunoglobulin compositions

    Actinium Phamaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  22. US 11407813

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  23. US 11400066

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  24. US 11400105

    Anti-inflammatory properties of marine lipid compositions

    AKER BIOMARINE ANTARCTIC AS · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.